Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:10 AM
Ignite Modification Date:
2025-12-25 @ 4:10 AM
NCT ID:
NCT06383520
Eligibility Criteria:
Inclusion Criteria:
* 1: Voluntarily participate and the person or their legal representative can sign an informed consent form
* 2: Adult patients (18 years of age or older), regardless of gender
* 3: Patients with newly diagnosed hepatocellular carcinoma with high clinical suspicion or confirmation (supporting evidence including imaging data and histopathologic examination, etc.) who agree to undergo histopathologic examination (if not performed prior to imaging) or/and 18F-FDG PET imaging
* 4: Healthy volunteer
* 5: Patients with a history of hepatocellular carcinoma, remission and recurrence after treatment
* 6: Willing and able to follow schedule visits, treatment plans and laboratory tests
Exclusion Criteria:
* 1: Pregnant or lactating patients
* 2: The patient or their legal representative is unable or unwilling to sign the informed consent form
* 3: Acute systemic diseases and electrolyte disorders
* 4: Patients who are known to be allergic to GPC3 imaging agents or synthetic excipients
* 5: Fasting blood glucose levels exceeding 11.0 mmol/L before injection of 18F-FDG
* 6: Individuals who are unable to complete PET/MR or PET/CT examinations (including inability to lie flat, claustrophobia, radiation phobia, etc.)
* 7: Researchers believe that compliance is poor or there are other unfavorable factors for participating in this experiment
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT06383520
Study Brief:
Protocol Section:
NCT06383520